Vaccines Market Will Reach $49.8bn Worldwide In 2020, According To New Visiongain Data

10 September 2018
Pharma

A new report by visiongain forecasts that overall sales of human vaccines will reach $49.8 billion worldwide in 2020. That revenue growth will continue steadily through to 2026, especially with advances in vaccine technology. That revenue prediction and others appear in Vaccine Sales Analysis 2016-2026: Discover Market Trends, R&D and Revenue Forecasts for Protecting Children, Adults and Elderly People from Diseases. The new study appears in March 2016.

Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help organisations understand technological and commercial prospects of industries and markets in healthcare and other fields.

Visiongain’s updated study analyses events, prospects and sales opportunities shaping the development, production and marketing of vaccines. That investigation shows multilevel revenue forecasting and qualitative assessments. The work also explores activities of companies providing these vaccines, assessing their potentials from 2016. The human vaccines market holds many commercial opportunities from 2016, including rising sales in developed and emerging countries.

Visiongain predicts that the global vaccines market will continue to grow at a steady pace from 2016 to 2026. That sales expansion will be stimulated by ageing populations and the increasing prevalence of infectious and chronic diseases. Also, with globalisation, demand for travel vaccines will increase. Adding to this will be the rising demand from underdeveloped and rising countries – as their economies improve, their healthcare expenditures rise, benefiting sales of vaccines.

Aanchal Verma, a pharmaceutical industry analyst in visiongain, said: “Vaccinations save billions of dollars each year by avoiding vaccine-preventable infections and reducing the disease and economic burden globally. As the world moves towards an ageing population, the elderly become more susceptible to contracting infections owing to their pre-existing conditions and weaker immune system, thereby boosting the demand for vaccines. Furthermore, high birth rates with poor sanitary conditions, but increasingly improved health care systems and vaccination routines in the emerging markets will greatly fuel demand for vaccines.

“Although the vaccine industry makes up a small segment for pharmaceutical companies, it represents a dynamic and robust growth market. With the increased awareness of the benefits of vaccinations across the world, the demand for immunisation programmes increases. Furthermore, developments in vaccine technology, delivery, efficacy and novel disease targeting will drive the long-term growth of the human vaccines industry.”

Visiongain’s new investigation gives individual revenue predictions to 2026 for four vaccine submarkets at world level:

• Paediatric vaccines
• Adult vaccines
• Elderly vaccines
• Travel vaccines.

That analysis also shows 10 revenue forecasts to 2026 for leading vaccines, including these:

• Prevnar
• Gardasil
• Fluzone
• Pentacel
• ProQuad/M-M-R- II/Varivax.

The study also shows prospects for vaccine sales in developed and developing regions, with individual revenue forecasts to 2026 for 11 countries:

• United States (US)
• Japan
• Germany, France, United Kingdom, Italy and Spain
• Brazil, Russia, India and China.

In particular the analysis explores these six market leaders:

• GlaxoSmithKline
• Merck & Co.
• Sanofi
• Pfizer
• Johnson & Johnson
• AstraZeneca.

Visiongain’s updated report also analyses vaccines in research and development:

• Prophylactic vaccines
• Products for children
• Agents for protecting adults
• Treatments for older people
• Travel vaccination
• Therapeutic vaccines.

Vaccine Sales Analysis 2016-2026: Discover Market Trends, R&D and Revenue Forecasts for Protecting Children, Adults and Elderly People from Diseases adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, biotechnology, medical devices, diagnostics and outsourced services.

Recent News

“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions.

14 May 2019

Read

“Indian Pharmaceutical market set to grow to $71bn by 2024” says new Visiongain report

Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses.

09 May 2019

Read

“Global mRNA Vaccines and Therapeutics market set to grow to $5.5bn by 2024” says new Visiongain

The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations.

07 May 2019

Read

“Global Oncology Drugs market set to grow to $173bn by 2024” says new Visiongain report

The cancer treating drugs market will continue to grow over the next ten years.

03 May 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1